For example, Wabitsch et al. thoroughly investigated the in vitro and in vivo impacts of (HCQ) treatment on the PD-1 therapeutic efficacy using anti-PD-1-sensitive tumor cell lines (MC38, CT26, and RIL-175). This evidence concerns the gene PDCD1 and neoplasm.